RP-G28

a galacto-oligosaccharide for promoting adaptation of colonic flora to handle dietary lactose

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

1.	Ritter, Andrew J: 2 articles (04/2020 - 12/2013)
2.	Savaiano, Dennis A: 2 articles (04/2020 - 12/2013)
3.	Azcarate-Peril, M Andrea: 1 article (04/2020)
4.	Chey, William: 1 article (04/2020)
5.	Foyt, Howard: 1 article (04/2020)
6.	Sandborn, William: 1 article (04/2020)
7.	Chandler, Justin R: 1 article (12/2013)
8.	Foyt, Howard L: 1 article (12/2013)
9.	James, Gareth M: 1 article (12/2013)
10.	Klaenhammer, Todd R: 1 article (12/2013)

1.	Lactose Intolerance (Intolerance, Lactose) 04/10/2020 - "The efficacy and safety of RP-G28 in reducing symptoms of lactose intolerance were assessed in a blinded, randomized, placebo-controlled trial. " 12/13/2013 - "RP-G28 is novel galacto-oligosaccharide (GOS) being investigated to improve lactose digestion and the symptoms of lactose intolerance in affected patients. "
2.	Abdominal Pain (Pain, Abdominal) 12/13/2013 - "Fifty percent of RP-G28 subjects with abdominal pain at baseline reported no abdominal pain at the end of treatment and 30 days post treatment (p = 0.0190). "